Ras effectors

doi:10.1016/S0955-0674(96)80066-4

Current Opinion in Cell Biology

Volume 8, Issue 2, April 1996, Pages 197-204

https://doi.org/10.1016/S0955-0674(96)80066-4 Get rights and content

Abstract

The search for proteins which interact with the active GTP-bound form of Ras in order to transmit signals for proliferation, differentiation and oncogenesis has been a long one. Now there are several strong candidates for Ras effectors that include protein kinases, lipid kinases and guanine nucleotide exchange factors. Structural information on how one Ras-binding domain in an effector interacts with Ras-GTP has recently been obtained. Recent data show that transformation by Ras oncoproteins requires the activation of several signal transduction pathways, including those which transmit signals via members of the Rho family of GTPases.

References (64)

CJ Marshall
Specificity of receptor tyrosine kinase signalling: transient versus sustained extracellular signal-regulated kinase activation
Cell
(1995)
S Cowley et al.
Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells
Cell
(1994)
GA Martin et al.
GAP domains responsible for Ras p21-dependent inhibition of muscarinic atrial K+ channel currents
Science
(1992)
T Toda et al.
In yeast, RAS proteins are controlling elements of adenylate cyclase
Cell
(1985)
AB Vojtek et al.
Mammalian Ras interacts directly with the serine/threonine kinase Raf
Cell
(1993)
XF Zhang et al.
Normal and oncogenic p21^ras proteins bind to the amino-terminal regulatory domain of c-Raf-1
Nature
(1993)
F Hofer et al.
Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator
Proc Natl Acad Sci USA
(1994)
M Spaargaren et al.
Identification of the guanine nucleotide dissociation stimulator for Ral as a putative effector molecule of R-ras, H-ras and Rap
Proc Natl Acad Sci USA
(1994)
Q Hu et al.
Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase
Science
(1995)
B Yamamori et al.
Purification of a Ras-dependent mitogen-activated protein kinase kinase kinase from bovine brain cytosol and its identification as a complex of B-Raf and 14-3-3 proteins
J Biol Chem
(1995)

SJ Leevers et al.

Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane

Nature

(1994)

D Stokoe et al.

Activation of Raf as a result of recruitment to the plasma membrane

Science

(1994)

MA White et al.

Multiple Ras functions can contribute to mammalian cell transformation

Cell

(1995)

AC Lloyd et al.

p21H-ras induced morphological transformation and increases in c-myc expression are independent of functional protein kinase C

EMBO J

(1989)

RG Qui et al.

An essential role for Rac in Ras transformation

Nature

(1995)

T Satoh et al.

Involvement of ras p21 protein in signal-transduction pathways from interleukin-2, interleukin-3 and granulocyte/macrophage colony-stimulating factor, but not from interleukin 4

Proc Natl Acad Sci USA

(1991)

LS Mulcahy et al.

Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells

Nature

(1985)

MA Woodrow et al.

p21(ras) function is important for T-cell antigen receptor and protein kinase-C regulation of nuclear factor of activated T-cells

J Immunol

(1993)

EJ Van Corven et al.

Pertussis toxin-sensitive activation of p21ras by G protein-coupled receptor agonists in fibroblasts

Proc Natl Acad Sci USA

(1993)

EF Pai et al.

Structure of the guanine nucleotide domain of the Ha-ras oncogene product p21 in the triphosphate conformation

Nature

(1989)

MV Milburn et al.

Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins

Science

(1990)

EF Pai et al.

Refined crystal structure of the triphosphate conformation of H-ras at 1.35Å resolution: implications for the mechanism of GTP hydrolysis

EMBO J

(1990)

N Nassar et al.

The 2.2 Å crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue

Nature

(1995)

SA Moodie et al.

Different structural requirements within the switch II region of the Ras protein for interactions with specific downstream targets

Oncogene

(1995)

TR Brtva et al.

Two distinct Ras domains mediate interaction with Ras

J Biol Chem

(1995)

M Trahey et al.

Molecular cloning of two types of GAP complementary DNA from human placenta

Science

(1988)

GA Martin et al.

The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21

Cell

(1990)

RH Medema et al.

GTPase-activating protein SH2—SH3 domains induce gene expression in a Ras-dependent fashion

Mol Cell Biol

(1992)

M Duchesne et al.

Identification of the SH3 domain of GAP as an essential sequence for Ras-GAP-mediated signaling

Science

(1993)

Y Wang et al.

byr2, a Schizosaccharomyces pombe gene encoding a protein kinase capable of partial suppression of the ras1 mutant phenotype

Mol Cell Biol

(1991)

EC Chang et al.

Cooperative interaction of S. pombe proteins required for mating and morphogenesis

Cell

(1994)

B Dickson et al.

Genetics of signal transduction in invertebrates

Curr Opin Genet Dev

(1994)

Cited by (477)

Structural optimization of novel Ras modulator for treatment of Colorectal cancer by promoting β-catenin and Ras degradation
2023, Bioorganic Chemistry
Ras protein has been considered a fascinating target for anticancer therapy because its malfunction is closely related to cancer. However, Ras has been considered undruggable because of the failure to regulate its malfunction by controlling the Ras activation mechanism. Recently, Lumakras targeting the G12C mutation was approved, and therapeutic interest in Ras for anticancer therapy has been rejuvenated. Here, we present a series of compounds that inhibit Ras via a unique mechanism of action that exploits the relationship between the Wnt/β-catenin pathway and Ras. KYA1797K (1) binds to axin to stabilize the β-catenin destruction complex that causes the phosphorylation and subsequent degradation of Ras, similar to canonical β-catenin regulation. Based on the chemical structure of 1, we performed a structural optimization and identified 3-(2-hydroxyethyl)-5-((6-(4-nitrophenyl)pyridin-2-yl)methylene)thiazolidine-2,4-dione (13d) as the most potent compound. 13d displayed antitumor effects in a colorectal cancer model with enhanced inhibition activity on Ras. The results of this study suggest that the further development of 13d could contribute to the development of Ras inhibitors with novel mechanisms of action.
Ras and Ras Signaling as a Therapeutic Target in Cancer
2022, Comprehensive Pharmacology
Ras is a family of small GTPases that controls many cellular phenotypes important to both normal and cancer cells through activation of downstream signaling. Mutations in Ras are among the most common drivers of tumorigenesis and tumor progression, and occur in about one-third of all cancers. Due to the prevalence of these mutations in a large variety of different tumor types and its critical role in carcinogenesis, Ras became a prominent therapeutic target. Attempts at inhibiting Ras, however, have been difficult with many drugs proving to be ineffective, ultimately leading to the labeling of Ras as “undruggable.” Despite these setbacks, increased knowledge surrounding Ras biology has led to renewed efforts in the pursuit of suppressing this protein by using diverse approaches including inhibitors focused on direct Ras activation, signaling effectors and regulators, post-translational processing, and metabolic and immunological changes. This article covers the early struggles of Ras therapies, the development of these new drugs and how they fare in preclinical and early phase clinical trials, as well as some new potential therapies that are on the horizon.
Emerging roles of protein O-GlcNAcylation in cardiovascular diseases: Insights and novel therapeutic targets
2021, Pharmacological Research
Cardiovascular diseases (CVDs) are the leading cause of death globally. While the major focus of pharmacological and non-pharmacological interventions has been on targeting disease pathophysiology and limiting predisposing factors, our understanding of the cellular and molecular mechanisms underlying the pathogenesis of CVDs remains incomplete. One mechanism that has recently emerged is protein O-GlcNAcylation. This is a dynamic, site-specific reversible post-translational modification of serine and threonine residues on target proteins and is controlled by two enzymes: O-linked β-N-acetylglucosamine transferase (OGT) and O-linked β-N-acetylglucosaminidase (OGA). Protein O-GlcNAcylation alters the cellular functions of these target proteins which play vital roles in pathways that modulate vascular homeostasis and cardiac function. Through this review, we aim to give insights on the role of protein O-GlcNAcylation in cardiovascular diseases and identify potential therapeutic targets in this pathway for development of more effective medicines to improve patient outcomes.
Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene
2020, Life Sciences
Non-small cell lung cancer (NSCLC) with RAS -mutant gene has been the most difficult obstacle to overcome. Over 25% of muted lung adenocarcinomas have RAS mutation. The prognosis of NSCLC patients with RAS-mutant genes is always poor because there is no effective drug to suppress RAS-mutant genes. NSCLC patients with RAS-mutant usually develop resistance to radiotherapy and chemotherapy, which in some cases leads to a 5–10% survival rate for non-small cell lung cancer (NSCLC). As little clinical symptom of NSCLC was presented at its early stages, thus it always brings in disappointing treatment outcome. Currently, NSCLC presents the highest morbidity and mortality all over the world. The combination of PI3K/AKT/mTOR pathway inhibitors with radiotherapy is a novel strategy to improve radiosensitivity and therapeutic outcome of NSCLC with a RAS-mutant gene. There have been many preclinical studies and clinical trials on the effect of PI3K/AKT/mTOR pathway inhibitors combined with radiotherapy in NSCLC with a RAS-mutant gene have been reported in the past years. This review provides current knowledge of the combination of PI3K/Akt/mTOR pathway inhibitors with radiotherapy, which prove to be a significant improvement for the treatment of NSCLC patients with RAS mutations and will benefit NSCLC patients with RAS mutations.
Involvement of H-Ras in the adaptive immunity of Nile tilapia by regulating lymphocyte activation
2019, Fish and Shellfish Immunology
H-Ras is a guanosine triphosphatase (GTPase), which acts as a molecular switch and controls multiple important cellular processes including lymphocyte activation and function. However, regulatory mechanism of adaptive immune response by H-Ras remains unclear in non-mammalian animals. In the present study, we investigated the involvement of H-Ras in lymphocyte activation with a teleost model Oreochromis niloticus. H-Ras from O. niloticus (On-H-Ras) is highly conserved with those from other vertebrates. The mRNA of On-H-Ras showed a wide expression pattern in the lymphoid-tissues and with the highest level in liver. After Aeromonas hydrophila infection, transcription of On-H-Ras was significantly induced on day 8 but came back to basal level on day 16, suggesting that On-H-Ras potentially participated in primary response during the adaptive immunity. Furthermore, On-H-Ras mRNA was obviously up-regulated when leukocytes were activated by T lymphocyte mitogen PHA in vitro. Meanwhile, protein level of H-Ras was also augmented once leukocytes were stimulated with lymphocyte receptor signaling agonist PMA and ionomycin. More importantly, once Ras activity was inhibited by specific inhibitor, the up-regulation of lymphocyte activation marker CD122 was obviously impaired during lymphocyte activation process. Therefore, On-H-Ras regulated lymphocyte activation through both mRNA and protein level. Altogether, our results illustrated the involvement of H-Ras in teleost adaptive immunity via controlling lymphocyte activation, and thus provided a novel perspective to understand evolution of the lymphocyte-mediated adaptive immunity.
RASpecting the oncogene: New pathways to therapeutic advances
2018, Biochemical Pharmacology
RAS is the most commonly mutated driver of tumorigenesis, seen in about 30% of all cancer cases. There is a subset of tumors termed RAS-driven cancers in which RAS mutation or overactivation is evident, including as much as 95% in pancreatic and 50% in colon cancer. RAS is a family of small membrane bound GTPases that act as a signaling node to control both normal and cancer biology. Since the discovery of RAS’ overall prominence in many tumor types and specifically in RAS-dependent cancers, it has been an obvious therapeutic target for drug development. However, RAS has proved a very elusive target, and after a few prominent RAS targeted drugs failed in clinical trials after decades of research, RAS was termed “undruggable” and research in this field was greatly hampered. An increase in knowledge about basic RAS biology has led to a resurgence in the generation of novel therapeutics targeting RAS signaling utilizing various and distinct approaches. These new drugs target RAS activation directly, block downstream signaling effectors and inhibit proper post-translational processing and trafficking/recycling of RAS. This review will cover how these new drugs were developed and how they have fared in preclinical and early phase clinical trials.

View all citing articles on Scopus

View full text